November 6, 2023- Medaxis and Medela’s wound care division will merge as a standalone business. Medela announced it will transition its wound care business into a separate global company. This new standalone wound care company will continue to provide wound care solutions powered by Medela’s medical vacuum technology including Medela’s Negative Pressure Wound Therapy (NPWT) line of products and services.
Chronic, non-healing wounds are a global public health challenge associated with significant physical and economic burdens for patients and health care systems. Common types of wounds include pressure injuries, diabetic foot ulcers, arterial and venous insufficiency ulcers, traumatic wounds, burns, and post-surgical incisions, among others. Medela’s technologies such as Intelligent Pressure Control and Dynamic Exudate Removal technology in Invia systems have set a new standard for NPWT and can help heal complex wounds more effectively, reducing healing time, and improving quality of life for patients.
The new standalone company will also incorporate the latest technology in wound therapy from medaxis, to provide unique solutions to advance healing and improve health outcomes. The medaxis technology helps support neovascularization and tissue growth, increases cellular activity and circulation, and supports bacterial load reduction. Medaxis is a swiss medical technology company that is a part of Olle Larsson Holding (OLH).
Effective December 1, Jeff Castillo will transition from Executive Vice President of Medela Americas to lead the new wound care company as CEO. Prior to his role at Medela, Jeff served in several medical device leadership positions, including Johnson and Johnson (J&J), Abbott and Merz, driving commercial results, innovation and focused, strategic acquisitions. Given this experience as well as his industry expertise in the wound care market, including the NPWT portfolio, Jeff is the ideal executive to lead the new standalone wound care company.